go back

Ciltacabtagene Autoleucel (Carvykti)

Rhode Island rates for HCPCS C9098

Ciltacabtagene autoleucel, up to 100 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $489,779 · 10th–90th $489,779$524,8070%50%90th$489,779Professionalmedian $501,187 · 10th–90th $501,187$501,1870%50%100%$501,187$500.0K

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Small sample; interpret with caution. Need provider-level prices? Contact us.

Insurance Carrier
BCBS
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$524,807.46
BCBS
Setting
Professional
Modifier
Global
Typical Low
$501,187.23
Median
$501,187.23
Typical High
$501,187.23